Condition

Psoriasis

Clinical trials and treatment information for Psoriasis, an autoimmune skin disease causing red, scaly patches.

60M
People Affected
40
Active Trials
1.2M
New Cases/Year
692
Deaths/Year

Treatment Rankings

Ranked by evidence volume first. Medicine has spent centuries ranking things by vibes. This is an improvement.

1
Ixekizumab
90% Effectiveness• 95% Confidence• 58% Safety• 48 trials• 15K participants
HIGH EvidencePoor ValueDose: 160mg SC at week 0, then 80mg SC every 2 weeks for 12 weeks, then every 4 weeks
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
58
DangerousModerateSafe

Time to Effect

2-4 weeks

Duration

lifetime

Response Rate

82%

Remission Rate

35%

Number Needed to Treat (NNT)

2

Number Needed to Harm (NNH)

75

Common Side Effects:

Nasopharyngitis: 11.6%
Upper respiratory tract infection: 10.3%
Injection site reaction: 16.2%
Oral candidiasis: 2.1%

Annual Cost of Care

Drug Cost

$98,000

Monitoring

$600

Side Effects

$500

Total Annual

$99,100

Cost-Effectiveness

POOR

QALYs Gained

1.4

ICER

$160,000/QALY

Cost per Remission

$283,143

Cost per Responder

$120,854

Treatment Outcomes
Primary Outcomes
PASI Score (Psoriasis Area and Severity Index)18.0 points on a 0-72 scale
-85% (-15.3 points)
sPGA Score (Static Physician's Global Assessment)3.0 (Moderate) on a 0-5 scale
-66.7% (-2.0 points)
Body Surface Area (BSA) affected by psoriasis15.0%
-85% (-12.75%)
Secondary Benefits
DLQI Score (Dermatology Life Quality Index)14.0 points on a 0-30 scale
-80% (-11.2 points)
Itch Numeric Rating Scale (NRS)7.5 points on a 0-10 scale
-80% (-6.0 points)
HADS-A Score (Hospital Anxiety and Depression Scale - Anxiety)11.0 points on a 0-21 scale
-50% (-5.5 points)
Common Side Effects
Nasopharyngitis
+11.6%
Upper respiratory tract infection
+10.3%
Injection site reaction
+16.2%

Clinical Trial Phases:

Phase 3Phase 4
2
Guselkumab
88% Effectiveness• 93% Confidence• 60% Safety• 61 trials• 12K participants
HIGH EvidencePoor ValueDose: 100mg SC at weeks 0, 4, then every 8 weeks
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe

Time to Effect

4-12 weeks

Duration

lifetime

Response Rate

84%

Remission Rate

40%

Number Needed to Treat (NNT)

2

Number Needed to Harm (NNH)

80

Common Side Effects:

Upper respiratory tract infection: 12.6%
Headache: 10.4%
Injection site reactions: 7.5%
Gastroenteritis: 3.4%

Annual Cost of Care

Drug Cost

$97,000

Monitoring

$600

Side Effects

$500

Total Annual

$98,100

Cost-Effectiveness

POOR

QALYs Gained

1.5

ICER

$155,000/QALY

Cost per Remission

$245,250

Cost per Responder

$116,786

Treatment Outcomes
Primary Outcomes
PASI ScorePASI score: 20
-88% (-17.6 points)
Investigator's Global Assessment (IGA) ScoreIGA Score: 3.5 (moderate/severe)
-80% (-2.8 points)
Body Surface Area (BSA) affected by Psoriasis15% BSA affected
-86.7% (-13 percentage points)
Secondary Benefits
Dermatology Life Quality Index (DLQI)DLQI Score: 13/30
-69.2% (-9 points)
Itch Numeric Rating Scale (NRS)Itch NRS: 7/10
-64.3% (-4.5 points)
Psoriasis Symptom and Sign Daily Diary (PSSD) Total Symptom ScorePSSD Total Symptom Score: 20/40
-70% (-14 points)
Common Side Effects
Upper respiratory tract infection
+12.6%
Headache
+10.4%
Injection site reactions
+7.5%

Clinical Trial Phases:

Phase 3Phase 4
3
Secukinumab
85% Effectiveness• 94% Confidence• 58% Safety• 141 trials• 18K participants
HIGH EvidenceModerate ValueDose: 300mg SC at weeks 0, 1, 2, 3, 4, then every 4 weeks
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
58
DangerousModerateSafe

Time to Effect

2-4 weeks

Duration

lifetime

Response Rate

77%

Remission Rate

30%

Number Needed to Treat (NNT)

2

Number Needed to Harm (NNH)

70

Common Side Effects:

Nasopharyngitis: 12.3%
Diarrhea: 4.1%
Upper respiratory tract infection: 9.5%
Oral candidiasis: 1.7%

Annual Cost of Care

Drug Cost

$95,000

Monitoring

$600

Side Effects

$500

Total Annual

$96,100

Cost-Effectiveness

MODERATE

QALYs Gained

1.3

ICER

$150,000/QALY

Cost per Remission

$320,333

Cost per Responder

$124,805

Treatment Outcomes
Primary Outcomes
PASI Score20.0 (0-72 scale)
-85% (-17.0 points)
sPGA Score3.5 (0-5 scale)
-71.4% (-2.5 points)
DLQI Score14.0 (0-30 scale)
-71.4% (-10.0 points)
Secondary Benefits
Itch Severity (NRS)7.0 (0-10 scale)
-64.3% (-4.5 points)
NAPSI Score25.0 (0-80 scale)
-50% (-12.5 points)
Body Surface Area (BSA) Involvement20%
-80% (-16%)
Common Side Effects
Nasopharyngitis
+12.3%
Diarrhea
+4.1%
Upper respiratory tract infection
+9.5%

Clinical Trial Phases:

Phase 3Phase 4
4
Ustekinumab
80% Effectiveness• 96% Confidence• 57% Safety• 94 trials• 20K participants
HIGH EvidenceExcellent ValueDose: 45mg or 90mg SC at weeks 0, 4, then every 12 weeks
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
57
DangerousModerateSafe

Time to Effect

4-12 weeks

Duration

lifetime

Response Rate

67%

Remission Rate

25%

Number Needed to Treat (NNT)

2.5

Number Needed to Harm (NNH)

100

Common Side Effects:

Nasopharyngitis: 11.2%
Upper respiratory tract infection: 9.8%
Headache: 8.7%
Injection site erythema: 5.1%

Annual Cost of Care

Drug Cost

$90,000

Monitoring

$600

Side Effects

$500

Total Annual

$91,100

Cost-Effectiveness

EXCELLENT

QALYs Gained

1.2

ICER

$35,000/QALY

Cost per Remission

$364,400

Cost per Responder

$135,970

Treatment Outcomes
Primary Outcomes
Psoriasis Area and Severity Index (PASI) Score22/72
-75% (-16.5 points)
Static Physician's Global Assessment (sPGA) Score3.5/5
-71.4% (-2.5 points)
Body Surface Area (BSA) affected by Psoriasis18%
-83.3% (-15%)
Secondary Benefits
Dermatology Life Quality Index (DLQI) Score16/30
-75% (-12 points)
Itch Numeric Rating Scale (NRS)6.5/10
-53.8% (-3.5 points)
Nail Psoriasis Severity Index (NAPSI) Score25/80
-48% (-12 points)
Common Side Effects
Nasopharyngitis
+11.2%
Upper respiratory tract infection
+9.8%
Headache
+8.7%

Clinical Trial Phases:

Phase 3Phase 4
5
Adalimumab
75% Effectiveness• 98% Confidence• 52% Safety• 175 trials• 30K participants
HIGH EvidenceGood ValueDose: 80mg SC at week 0, then 40mg SC every other week starting week 1
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
52
DangerousModerateSafe

Time to Effect

4-12 weeks

Duration

lifetime

Response Rate

71%

Remission Rate

20%

Number Needed to Treat (NNT)

2.5

Number Needed to Harm (NNH)

85

Common Side Effects:

Injection site reaction: 12.9%
Upper respiratory tract infection: 12.3%
Headache: 8.7%
Rash: 5.5%

Annual Cost of Care

Drug Cost

$60,000

Monitoring

$600

Side Effects

$800

Total Annual

$61,400

Cost-Effectiveness

GOOD

QALYs Gained

1

ICER

$100,000/QALY

Cost per Remission

$307,000

Cost per Responder

$86,479

Treatment Outcomes
Primary Outcomes
Psoriasis Area and Severity Index (PASI) Score18 (0-72 scale)
-75% (-13.5 points)
Physician's Global Assessment (PGA) Score3 (Moderate, 0-4 scale)
-66.7% (-2 points (to 'Minimal' or 'Clear'))
Body Surface Area (BSA) Affected15%
-66.7% (-10% BSA)
Dermatology Life Quality Index (DLQI) Score18 (0-30 scale)
-44.4% (-8 points)
Secondary Benefits
Tender Joint Count (TJC)12 joints (for co-existing Psoriatic Arthritis)
-50% (-6 joints)
C-reactive Protein (CRP)8 mg/L
-50% (-4 mg/L)
Itch Severity Visual Analog Scale (VAS)8 (0-10 scale)
-62.5% (-5 points)
Common Side Effects
Injection site reaction
+12.9%
Upper respiratory tract infection
+12.3%
Headache
+8.7%

Clinical Trial Phases:

Phase 3Phase 4
6
Apremilast
35% Effectiveness• 90% Confidence• 72% Safety• 94 trials• 10K participants
HIGH EvidencePoor ValueDose: 30mg BID
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
72
DangerousModerateSafe

Time to Effect

12-16 weeks

Duration

lifetime

Response Rate

25%

Remission Rate

3%

Number Needed to Treat (NNT)

6

Number Needed to Harm (NNH)

120

Common Side Effects:

Nausea: 17.5%
Diarrhea: 17%
Headache: 15.5%
Upper respiratory tract infection: 9.9%

Annual Cost of Care

Drug Cost

$45,000

Monitoring

$300

Side Effects

$200

Total Annual

$45,500

Cost-Effectiveness

POOR

QALYs Gained

0.4

ICER

$180,000/QALY

Cost per Remission

$1,516,667

Cost per Responder

$182,000

Treatment Outcomes
Primary Outcomes
PASI (Psoriasis Area and Severity Index) Score18.0 points (0-72 scale)
-50% (-9.0 points)
sPGA (static Physician's Global Assessment) Score3.0 points (0-4 scale, Moderate)
-33.3% (-1.0 point)
Body Surface Area (BSA) affected by Psoriasis15.0% of total BSA
-45% (-6.75% of total BSA)
Secondary Benefits
Psoriasis Itch Numeric Rating Scale (NRS) Score7.0 points (0-10 scale)
-35% (-2.45 points)
DLQI (Dermatology Life Quality Index) Score18.0 points (0-30 scale)
-40% (-7.2 points)
Scalp Psoriasis Severity Index (PSSI) Score14.0 points (0-72 scale)
-45% (-6.3 points)
Common Side Effects
Nausea
+17.5%
Diarrhea
+17%
Headache
+15.5%

Clinical Trial Phases:

Phase 3Phase 4
7
Methotrexate
30% Effectiveness• 99% Confidence• 30% Safety• 104 trials• 25K participants
HIGH EvidenceExcellent ValueDose: 7.5-25mg once weekly
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe

Time to Effect

6-12 weeks

Duration

long-term

Response Rate

35%

Remission Rate

4%

Number Needed to Treat (NNT)

4

Number Needed to Harm (NNH)

15

Common Side Effects:

Nausea: 20%
Fatigue: 15%
Elevated liver enzymes: 10%
Stomatitis: 5%

Annual Cost of Care

Drug Cost

$400

Monitoring

$1,100

Side Effects

$300

Total Annual

$1,800

Cost-Effectiveness

EXCELLENT

QALYs Gained

0.6

ICER

$15,000/QALY

Cost per Remission

$45,000

Cost per Responder

$5,143

Treatment Outcomes
Primary Outcomes
PASI Score18 (on a 0-72 scale)
-60% (-10.8 points)
Body Surface Area Affected15%
-50% (-7.5% of BSA)
Investigator's Global Assessment (IGA)3 (moderate, on a 0-4 scale)
-66.7% (-2 grades (e.g., from moderate to clear/minimal))
Secondary Benefits
Dermatology Life Quality Index (DLQI)14 (on a 0-30 scale)
-50% (-7 points)
Itch Severity (NRS)7 (on a 0-10 scale)
-42.8% (-3 points)
C-reactive protein (CRP)5 mg/L
-30% (-1.5 mg/L)
Common Side Effects
Nausea
+20%
Fatigue
+15%
Elevated liver enzymes
+10%

Clinical Trial Phases:

Phase 4